Chemotherapy for desmoid tumours in association with familial adenomatous polyposis: a report of three cases |
| |
Authors: | Lisa Hamilton Martin Blackstein Terri Berk Robin S. McLeod Steven Gallinger Lisa Madlensky Zane Cohen |
| |
Affiliation: | Steve Atanas Stavro Polyposis Registry, Mount Sinai Hospital, and the University of Toronto, Toronto, Ont. |
| |
Abstract: |
ObjectiveTo determine the efficacy of chemotherapy for inoperable desmoid tumours associated with familial adenomatous polyposis.DesignA review of three cases of unresectable desmoid tumours and of the literature on the subject.SettingThe Steven Atanas Stavro Polyposis Registry at Mount Sinai Hospital in Toronto.PatientsThree patients with symptomatic, unresectable desmoid tumours associated with familial adenomatous polyposis and unresponsive to conventional hormone therapy.InterventionA chemotherapy regimen of seven cycles of doxorubicin (dose ranging from 60 to 90 mg/m2) and dacarbazine (1000 mg/m2), followed by carboplatin (400 mg/m2) and dacarbazine.Outcome MeasuresClinical improvement and tumour regression demonstrated by computed tomography.ResultsIn each of the three cases significant tumour regression was seen clinically and radiologically.ConclusionsCytotoxic chemotherapy is an effective treatment for desmoid tumours associated with familial adenomatous polyposis. The chemotherapy should be started early in cases of symptomatic desmoid tumour unresponsive to conventional medical therapy. |
| |
Keywords: | |
|
|